Sources Listing Archive
Archived Listing - Last Updated: March 2002. This information represents a historical archive of listings which appeared in SOURCES, which has been continuously published in print and online since 1977. The information has not been updated since the date indicated. For current information consult the SOURCES website at www.sources.com. To be included in the current SOURCES listings, and to take advantage of other tools including unlimited news releases and event calendar postings, fill out the online membership form. For more information, see Frequently Asked Questions or call 416-964-7799.
Micrologix Biotech develops novel drugs targeted at severe and life-threatening diseases -- particularly those caused by antibiotic-resistant bacteria. Micrologix currently has two drugs in clinical trials in the United States: MBI 226 for the prevention of catheter-related bloodstream infections and MBI 594AN for the treatment of acne. TSE listed: MBI. Included in the TSE 300 Composite Index.
Areas of Expertise:
For information or updates contact Sources at 416-964-7799
or see our current publications and services online:
© Sources 1977-2012. The information provided
is copyright and may not be reproduced in any form or by any means (whether
electronic, mechanical or photographic), or stored in an electronic
retrieval system, without written permission of the publisher. The content
may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.